Debt to EBITDA ratio Analysis of Eagle Pharmaceuticals Inc - Deep Dive
Birds's Eye
Fundamentals
Fundamentals
Technicals
MovingAverage
Candlestick
PivotPointDebt to EBITDA of EGRX
Dec-220.954Excellent Debt to EBITDA | Dec-21-10.57Very Poor Debt to EBITDA | Growth109.03% |
Debt to EBITDA Analysis of Eagle Pharmaceuticals Inc
| Debt to EBITDA Ratio 0.954 of Eagle Pharmaceuticals Inc shows that the company is financially strong and has enough profit to pay off its debt. |
| Debt to EBITDA Ratio of EGRX rose handsomely by 109.03 % this year. |
| Debt to EBITDA Ratio with value of 1.31 was highest in Year Dec-19 in last Five Years. |
| Debt to EBITDA Ratio with value of -10.57 was lowest in Year Dec-21 in last Five Years. |
| Latest Debt to EBITDA Ratio with value of 0.954 is Greater than Average Debt to EBITDA of -1.22 in last five years. |
Other Debt to EBITDA Related Info of EGRX that may interest you.
Eagle Pharmaceuticals Inc Overview
| Code | Price | Previous Price | Price Change | Sector |
|---|---|---|---|---|
| EGRX | 4.06 | 3.85 | 5.45 % | Drug Manufacturers-Specialty & Generic |
Defination of Debt to EBITDA
The Debt to EBITDA Ratio is a solvency metric that measures the company's ability to meet its debt obligations by earnings before covering its interest, taxes, depreciation, and amortization. more ..
Debt to EBITDA Related Ratios
| CashFlowFromOperationToDebt | DebtToCapital | EVToEBITDA |
Tsr Stability Index
| Good Stability | |
FY - Historical Debt to EBITDA of Eagle Pharmaceuticals Inc
| Period | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|
| Debt to EBITDA | 0.954 | -10.57 | 1.10 | 1.31 | 1.10 | 0.614 | 0 |
| Change | 109.03 % | -1057.48 % | -16.02 % | 19.71 % | 78.84 % | 0 % |
FY Chart of Debt to EBITDA of Eagle Pharmaceuticals Inc
Note : All Data Generated at the End of Trading Hours (EOD Data)